Multiple myeloma trials in Belgium

In Belgium 31 Also abroad 704

31 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Where
Antwerp, Roeselare
Age
18 years and over
People
410 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT05730036 · EU 2022-501396-62-00
Phase 3Taking people
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Where
Antwerp, Brugge, Genk, Jette, Liège, Yvoir
Age
18 years and over
People
915 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT07222761 · EU 2024-519504-27-00
Phase 2Taking people
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Edegem, Leuven, Liège, Sint-Lambrechts-Woluwe
Age
18 years and over
People
510 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT04634552 · EU 2023-504581-29-00
Phase 4Taking people
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Where
Edegem, Gent, Leuven
Age
18 years and over
People
295 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05201781 · EU 2023-505530-10-00
Phase 3Taking people
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Where
Anderlecht, Antwerp, Gent, Kortrijk, Leuven
Age
18 years and over
People
1,590 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00
Phase 1Taking people
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Where
Edegem, Gent, Liège
Age
18 years and over
People
180 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05652335 · EU 2023-503679-12-00
Phase 3Taking people
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Where
Antwerp, Genk, Ghent, Sint-Niklaas
Age
18 years and over
People
810 worldwide
Run by
Celgene
See details and how to joinNCT05519085
Phase 3Taking people
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Where
Edegem, Gent, Sint-Lambrechts-Woluwe, Yvoir
Age
18 years and over
People
440 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00
Phase 3Taking people
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Where
Brugge, Charleroi, Gent, Jette, Ottignies-Louvain-la-Neuve, Roeselare, Yvoir
Age
18 years and over
People
1,060 worldwide
Run by
Pfizer
See details and how to joinNCT05623020 · EU 2024-514139-50-00
Phase 1/2Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Where
Gent, Leuven, Liège
Age
18 years and over
People
325 worldwide
Run by
AbbVie
See details and how to joinNCT06953960 · EU 2024-517140-65-00
Phase 1/2Taking people
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Where
Antwerp, Brussels
Age
18 years and over
People
387 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT03761108 · EU 2024-511454-45-00
Phase 3Taking people
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Where
Edegem, Ghent, Liège, Roeselare
Age
18 years and over
People
63 worldwide
Run by
CSL Behring
See details and how to joinNCT07648264 · EU 2026-525626-38-00
Phase 3Taking people
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Where
Hasselt, La Louvière, Leuven, Liège, Roeselare
Age
18 years and over
People
1,594 worldwide
Run by
European Myeloma Network B.V.
See details and how to joinNCT05243797 · EU 2023-510384-36-00
Phase 3Taking people
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
Where
Anderlecht, Charleroi, Liège, Sint-Lambrechts-Woluwe, Yvoir
Age
18 years to 69 years
People
824 worldwide
Run by
Intergroupe Francophone du Myelome
See details and how to joinNCT06918002 · EU 2024-516418-39-00
No phaseTaking people
Study on the Clinical Efficacy of Teclistamab and Talquetamab
Where
Bonheiden, Brussels, Charleroi, Edegem, Ghent, Hasselt, Hornu, Kortrijk, Leuven, Liège, Mons, Roeselare, Sint-Niklaas, Yvoir
Age
18 years and over
People
100
Run by
Universitaire Ziekenhuizen KU Leuven
See details and how to joinNCT06477783
Phase 3Taking people
A long-term follow-up study for patients treated with Galapagos CAR T cell therapies
Where
Edegem, Leuven, Liège, Roeselare, Sint-Lambrechts-Woluwe
Age
18 years and over
People
309 worldwide
Run by
Lakefront Biotherapeutics
See details and how to join2023-510173-34-00 · EU 2023-510173-34-00
Phase 1/2Taking people
[68Ga]Ga-PentixaFor positron emission tomography for improved risk and disease assessment in myeloma
Where
Edegem, Gent, Leuven
Age
18 years and over
People
90 worldwide
Run by
University Of Antwerp
See details and how to join2022-501811-14-00 · EU 2022-501811-14-00
Phase 1Taking people
A study to evaluate the Safety, Pharmacokinetics, and Activity of Subcutaneous Cevostamab (BFCR4350A) in Patients with Relapsed or Refractory Multiple Myeloma (CAMMA 3)
Where
Gent, Jette
Age
18 years and over
People
45 worldwide
Run by
Genentech Inc.
See details and how to join2023-503404-89-00 · EU 2023-503404-89-00
Phase 3Taking people
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Where
Charleroi, Yvoir
Age
18 years and over
People
893 worldwide
Run by
Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00
Phase 3Taking people
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Where
Boussu, Charleroi, Gent, Jette, Ottignies-Louvain-la-Neuve, Roeselare, Verviers, Yvoir
Age
18 years and over
People
492 worldwide
Run by
Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00
Phase 1/2Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Where
Gent, Leuven, Liège
Age
18 years and over
People
88 worldwide
Run by
AbbVie Deutschland GmbH & Co. KG
See details and how to join2025-525105-20-00 · EU 2025-525105-20-00
Phase 2Taking people
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Where
Antwerp, Brasschaat, Brugge, Herentals, Mechelen, Roeselare
Age
18 years and over
People
116 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06140524 · EU 2023-505242-25-00
No phaseTaking people
Immune Fitness in Older Patients With Relapsed and Refractory Multiple Myeloma
Where
Anderlecht, Brussels, Woluwe-Saint-Lambert
Age
65 years and over
People
31
Run by
Jules Bordet Institute
See details and how to joinNCT07674498
No phaseTaking people
"Pseudo-scanner" MRI Sequences for the Detection of Bone Lesions in Multiple Myeloma
Where
Brussels
Age
18 years and over
People
45
Run by
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
See details and how to joinNCT06988020
Phase 3Taking people
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Where
Roeselare
Age
18 years and over
People
520 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06679101 · EU 2024-516030-35-00